New drug cocktail aims to outsmart resistant uterine cancer

NCT ID NCT03675893

Recruiting now Disease control Sponsor: Dana-Farber Cancer Institute Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This phase 2 trial tests whether combining hormone therapy (letrozole) with a targeted drug (abemaciclib), and possibly adding metformin or gedatolisib, can control estrogen-receptor-positive endometrial cancer that has returned or spread. The study enrolls adults with this cancer type who have few other options. Researchers measure how long participants live without the cancer growing and whether tumors shrink.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Letrozole, Abemaciclib, Metformin, Gedatolisib
What this could lead to: If successful, this could offer new combination treatment options for people with ER+ endometrial cancer that has stopped responding to standard therapies.
What could go wrong: This is an early-phase trial with a small number of participants. The drug combinations may cause side effects or fail to improve outcomes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ENDOMETRIAL CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

carcinosarcoma of the corpus uteri endometrial cancer endometrial endometrioid adenocarcinoma endometrium neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ENDOMETRIAL CANCER

Contacts and locations

Locations

Beth Israel Deaconess Medical Center (BIDMC)
RECRUITING

Boston, Massachusetts, 02215, United States
Dana Farber Cancer Institute
RECRUITING

Boston, Massachusetts, 02215, United States
Massachusetts General Hospital Cancer Center
RECRUITING

Boston, Massachusetts, 02214, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.